Compliance
COMMON COLD
Compliance at the start of investigational product use, defined as applying the product by the morning of the next day after the first day of a defined common cold, was similar in the two treatment groups, with 98.6% of subjects starting to use the investigational product in time as reported in the subject diary.Evaluation of compliance to investigational product usage was performed based on the return and weighing of unused investigational product as compared to duration of the period defined for usage. A compliance of at least 80% of the correct quantity of the investigational product was seen for 265/436 (60.8%) of subjects, with a higher compliance in the ColdZyme group (64.7%) compared to the placebo group (56.9%).